Insulet Corp
NASDAQ:PODD

  • LAST PRICE
    177.5300
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    162.1000/ 1
  • Ask / Lots
    173.4700/ 1
  • Open / Previous Close
    0.0000 / 177.5300
  • Day Range
    ---
  • 52 Week Range
    125.8200
    331.6500
  • Volume
    44

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

      Show headlines and story abstract

    • 13 hours ago by MT Newswires
      Companies Mentioned: PODD
      04:30 PM EDT, 05/09/2024 (MT Newswires) -- Insulet (PODD) late Thursday reported Q1 net income of $0.73 per diluted share, up from $0.34 a year earlier. Analysts polled by Capital IQ expected $0.40. Revenue for the quarter ended March 31 was $441.7...

    • 13 hours ago by MT Newswires
      Companies Mentioned: PODD
      04:05 PM EDT, 05/09/2024 (MT Newswires) -- ...

    • 13 hours ago by MT Newswires
      Companies Mentioned: PODD
      04:04 PM EDT, 05/09/2024 (MT Newswires) -- ...

    • 13 hours ago by Business Wire
      Companies Mentioned: PODD

      Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod(R) brand of products, today announced financial results for the three months ended March 31, 2024.

    • 13 hours ago by Dow Jones
      Companies Mentioned: PODD
      ------------ --- -------------- Total liabilities 1,833.3 1,855.5 Stockholders' equity 790.7 732.7 ------------ --- -------------- Total liabilities and stockholders' equity $ 2,624.0 $ 2,588.2 ============ === ============== INSULET CORPORATION NON-GAAP RECONCILIATIONS (UNAUDITED) CONSTANT CURRENCY REVENUE GROWTH Three Months Ended March 31, --------------- Percent Currency Constant (dollars in millions) 2024 2023 Change Impact Currency ------ ------- -------- -------- --------- Revenue: U.S. Omnipod $317.7 $ 259.0 22.7% --% 22.7% International Omnipod 115.3 98.6 16.9% 2.1% 14.8% ----- ------ Total Omnipod 433.0 357.6 21.1% 0.6% 20.5% Drug Delivery 8.7 0.5 1,640.0% --% 1,640.0% ----- ------ Total $441.7 $ 358.1 23.3% 0.5% 22.8% ===== ====== ADJUSTED GROSS MARGIN, OPERATING MARGIN, NET INCOME, DILUTED EPS Three Months Ended March 31, 2023 --------------------------------------------------------------------- Percent Percent Diluted Gross of Operating of Earnings (dollars in millions) Profit Revenue Income Revenue Net Income(2) per Share ------- ------- ------------- ------- ------------- ------------ GAAP $240.5 67.2% $ 27.7 7.7% $ 23.8 $ 0.34 Voluntary medical device correction(1) (8.0) (8.0) (8.0) (0.11) ----- ----- ----- ----- Non-GAAP $232.5 64.9% $ 19.7 5.5% $ 15.8 $ 0.23 ===== ===== ===== ===== ADJUSTED EBITDA Three Months Ended March 31, ------------------------------------- Percent of Percent of (dollars in millions) 2024 Revenue 2023 Revenue ----- ---------- ------ ---------- Net income $51.5 11.7% $23.8 6.6% Interest expense, net 1.3 2.9 Income tax expense 3.4 0.8 Depreciation and amortization 18.8 17.2 Stock-based compensation expense 14.2 12.1 Voluntary medical device corrections(1) -- (8.0) ---- ---- Adjusted EBITDA $89.2 20.2% $48.8 13.6% ==== ==== (1) Represents income resulting from an adjustment to estimated costs associated with the voluntary MDC notices issued in the fourth quarter of 2022, which is included in cost of revenue. (2) The tax effect on non-GAAP adjustments is calculated based on the applicable local statutory tax rates, including any valuation allowance. INSULET CORPORATION NON-GAAP RECONCILIATIONS (UNAUDITED) CONTINUED REVENUE GUIDANCE Year Ending December 31, 2024 -------------------------------------------------- Revenue Growth GAAP Currency Impact Constant Currency -------------- --------------- ----------------- U.S. Omnipod 17% - 21% --% 17% - 21% International Omnipod 11% - 14% (1)% 12% - 15% Total Omnipod 15% - 19% --% 15% - 19% Drug Delivery (60)% - (50)% --% (60)% - (50)% Total 14% - 18% --% 14% - 18% Three Months Ended June 30, 2024 -------------------------------------------------- Revenue Growth GAAP Currency Impact Constant Currency -------------- --------------- ----------------- U.S. Omnipod 21% - 24% --% 21% - 24% International Omnipod 10% - 13% (2)% 12% - 15% Total Omnipod 17% - 20% (1)% 18% - 21% Drug Delivery (75)% - (70)% --% (75)% - (70)% Total 14% - 17% (1)% 15% - 18%

Peers Headlines